drugset
drugset / Trial / NCT06083857

PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer

NCT06083857 ↗

Phase 1/2 Active not recruiting 3 enrolled M.D. Anderson Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

To learn if the combination of amivantamab and tepotinib can help to control NSCLC. The safety of this drug combination will also be studied.

Timeline

Start
2024-06-18
Primary completion
2027-12-31
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Amivantamab Monoclonal antibody — Intravenous
Subject Tepotinib Small molecule — Oral

Indications

non-small cell lung carcinoma